Septerna, a biotech company, has entered the market with a lack of human data but with promising technology based on research from a Nobel laureate. The company’s lead drug candidate, SEP-786, targets hypoparathyroidism, offering a potential advantage over current treatments for the rare disease. With $288 million in IPO funding, Septerna plans to continue clinical testing of SEP-786. The company’s platform technology, Native Complex, focuses on G protein coupled-receptors and has yielded potential treatments for metabolic disorders. Investors have shown interest in Septerna, allowing the company to increase its IPO size. Septerna aims to use the funding to advance its drug candidates and further develop its pipeline.
Source link
Septerna’s Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs
